Stock listing
LS Exchange:A2P72S Immatics N.V. Aktie
German listing (LS Exchange) of Immatics N.V. · home listing NASDAQ:IMTX
Follow Immatics N.V. into a list and get an email when it puts out news.
Home listing price · NASDAQ:IMTX
$5.77 USD -0.33 (-5.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IMTX
- Day range
- $5.72 – $5.95 USDNov 20, 2026
- Volume
- 746,637 sharesNov 20, 2026
- Market cap
- $878.3M USDAt the close on Nov 20, 2026 · price × 152.2M shares outstanding
- 52-week range
- $5.72 – $12.41 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.25M USDMedian day 761,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IMTX · Home | $5.77 USD | -0.33 (-5.4%) | 746,637 | $5.86 | $5.95 | $5.715 | $6.10 | Close on Nov 20, 2026 |
| Frankfurt:4A3 | €5.32 EUR | -0.195 (-3.5%) | — | €5.32 | €5.32 | €5.32 | €5.515 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.77 | -0.33 | -5.4% | $5.86 | $5.95 | $5.715 | 746,637 | |
| $6.10 | -0.19 | -3.0% | $6.27 | $6.41 | $6.06 | 1,571,164 | |
| $6.29 | +0.12 | +1.9% | $6.27 | $6.31 | $6.06 | 3,164,202 | |
| $6.17 | -0.22 | -3.4% | $6.33 | $6.57 | $6.07 | 762,156 | |
| $6.39 | -0.13 | -2.0% | $6.545 | $6.545 | $6.085 | 586,384 | |
| $6.52 | -0.17 | -2.5% | $6.64 | $6.89 | $6.34 | 762,489 | |
| $6.69 | +0.27 | +4.2% | $6.42 | $6.805 | $6.35 | 964,298 | |
| $6.42 | -0.01 | -0.2% | $6.32 | $6.78 | $6.20 | 1,221,136 | |
| $6.43 | +0.07 | +1.1% | $6.47 | $6.635 | $6.301 | 691,613 | |
| $6.36 | +0.18 | +2.9% | $6.18 | $6.42 | $6.10 | 1,063,382 | |
| $6.18 | -0.73 | -10.6% | $6.85 | $6.995 | $6.145 | 1,278,128 | |
| $6.91 | -0.165 | -2.3% | $7.25 | $7.515 | $6.89 | 678,233 | |
| $7.075 | +0.015 | +0.2% | $7.10 | $7.23 | $7.04 | 1,315,601 | |
| $7.06 | -0.14 | -1.9% | $7.24 | $7.35 | $7.00 | 1,023,170 | |
| $7.20 | -0.11 | -1.5% | $7.26 | $7.404 | $6.81 | 1,715,851 | |
| $7.31 | -0.04 | -0.5% | $7.35 | $7.523 | $7.20 | 1,178,901 | |
| $7.35 | +0.09 | +1.2% | $7.24 | $7.41 | $7.09 | 1,765,450 | |
| $7.26 | +0.11 | +1.5% | $7.19 | $7.385 | $7.00 | 1,193,657 | |
| $7.15 | -0.16 | -2.2% | $7.41 | $7.73 | $7.03 | 756,066 | |
| $7.31 | -0.23 | -3.1% | $7.46 | $7.50 | $7.25 | 695,978 | |
| $7.54 | -0.15 | -2.0% | $7.69 | $7.76 | $7.45 | 621,016 | |
| $7.69 | +0.18 | +2.4% | $7.62 | $7.95 | $7.61 | 1,980,384 | |
| $7.51 | +0.46 | +6.5% | $7.07 | $7.605 | $6.935 | 1,487,260 | |
| $7.05 | +0.32 | +4.8% | $6.85 | $7.20 | $6.72 | 967,122 | |
| $6.73 | -0.41 | -5.7% | $7.19 | $7.19 | $6.65 | 1,154,900 | |
| $7.14 | +0.14 | +2.0% | $7.05 | $7.21 | $6.948 | 1,627,800 | |
| $7.00 | +0.17 | +2.5% | $7.00 | $7.20 | $6.73 | 1,566,300 | |
| $6.83 | -0.38 | -5.3% | $7.17 | $7.28 | $6.80 | 928,000 | |
| $7.21 | -0.22 | -3.0% | $7.41 | $7.42 | $7.14 | 750,400 | |
| $7.43 | +0.06 | +0.8% | $7.37 | $7.45 | $7.21 | 1,371,300 | |
| $7.37 | -0.08 | -1.1% | $7.37 | $7.56 | $7.02 | 604,700 | |
| $7.45 | -0.05 | -0.7% | $7.44 | $7.70 | $7.31 | 926,000 | |
| $7.50 | -0.23 | -3.0% | $7.76 | $7.81 | $7.47 | 974,400 | |
| $7.73 | +0.14 | +1.8% | $7.57 | $7.85 | $7.47 | 554,100 | |
| $7.59 | -0.85 | -10.1% | $8.56 | $8.57 | $7.40 | 1,256,500 | |
| $8.44 | -0.34 | -3.9% | $8.72 | $8.845 | $8.43 | 639,700 | |
| $8.78 | +0.22 | +2.6% | $8.56 | $9.16 | $8.43 | 1,898,600 | |
| $8.56 | +0.06 | +0.7% | $8.50 | $8.695 | $8.39 | 644,300 | |
| $8.50 | +0.13 | +1.6% | $8.35 | $8.59 | $8.20 | 1,467,500 | |
| $8.37 | +0.04 | +0.5% | $8.39 | $8.50 | $8.25 | 378,800 | |
| $8.33 | -0.27 | -3.1% | $8.52 | $8.571 | $8.06 | 2,372,900 | |
| $8.60 | -0.27 | -3.0% | $8.80 | $8.89 | $8.575 | 384,200 | |
| $8.87 | +0.15 | +1.7% | $8.77 | $8.89 | $8.71 | 501,600 | |
| $8.72 | +0.10 | +1.2% | $8.76 | $8.87 | $8.58 | 305,300 | |
| $8.62 | -0.20 | -2.3% | $8.76 | $8.855 | $8.48 | 759,900 | |
| $8.82 | +0.18 | +2.1% | $8.97 | $9.04 | $8.74 | 427,700 | |
| $8.64 | +0.04 | +0.5% | $8.65 | $8.88 | $8.545 | 711,900 | |
| $8.60 | -0.02 | -0.2% | $8.59 | $8.77 | $8.335 | 355,800 | |
| $8.62 | -0.17 | -1.9% | $8.80 | $8.806 | $8.59 | 378,600 | |
| $8.79 | +0.04 | +0.5% | $8.84 | $8.921 | $8.535 | 527,200 | |
| $8.75 | -0.36 | -4.0% | $9.02 | $9.09 | $8.655 | 798,800 | |
| $9.11 | -0.33 | -3.5% | $9.38 | $9.555 | $9.085 | 326,100 | |
| $9.44 | -0.12 | -1.3% | $9.37 | $9.515 | $9.31 | 699,500 | |
| $9.56 | +0.10 | +1.1% | $9.34 | $9.57 | $9.30 | 497,200 | |
| $9.46 | -0.04 | -0.4% | $9.53 | $9.69 | $9.26 | 494,300 | |
| $9.50 | +0.07 | +0.7% | $9.47 | $9.723 | $9.295 | 761,100 | |
| $9.43 | -0.10 | -1.0% | $9.38 | $9.60 | $9.23 | 607,100 | |
| $9.53 | +0.08 | +0.8% | $9.36 | $9.55 | $9.231 | 725,000 | |
| $9.45 | +0.09 | +1.0% | $9.68 | $9.89 | $9.32 | 1,094,200 | |
| $9.36 | -0.07 | -0.7% | $9.36 | $9.48 | $9.177 | 742,200 | |
| $9.43 | +0.19 | +2.1% | $9.22 | $9.465 | $8.97 | 778,000 | |
| $9.24 | +0.55 | +6.3% | $9.59 | $9.75 | $9.04 | 1,062,766 | |
| $8.69 | -0.24 | -2.7% | $8.86 | $8.905 | $8.56 | 338,149 | |
| $8.93 | +0.38 | +4.4% | $8.60 | $9.05 | $8.60 | 611,200 | |
| $8.55 | -0.70 | -7.6% | $9.12 | $9.13 | $8.40 | 474,800 |
- Ticker
- LS Exchange:A2P72S
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LS Exchange
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Immatics Announces Third Quarter 2026 Financial Results and Business Update
Latest deck · Oct 26, 2026
Investor Presentation (October 2026)
Investor deck · 63 slides
Latest news
Immatics Announces Third Quarter 2026 Financial Results and Business Update
Nov 10, 2026
Closed $6.42 (-0.2%) on Nov 10, 2026
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Oct 24, 2026
Closed $7.15 (-2.2%) on Oct 26, 2026
Immatics Announces $150 Million Underwritten Offering
Aug 25, 2026
Closed $9.24 (+6.3%) on Aug 25, 2026
Immatics N Announces Second Quarter 2026 Financial Results and Business Update
Aug 18, 2026
Closed $9.09 (-1.7%) on Aug 18, 2026
Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Cancer Vaccine Candidate ITI-5000
Jul 20, 2026
Closed $9.23 (-3.8%) on Jul 20, 2026
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
Jul 17, 2026
Closed $9.59 (+2.0%) on Jul 17, 2026
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Jun 1, 2026
Closed $11.14 (-3.2%) on Jun 1, 2026
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
May 31, 2026
Closed $11.14 (-3.2%) on Jun 1, 2026
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
May 30, 2026
Closed $11.14 (-3.2%) on Jun 1, 2026
Immatics Announces First Quarter 2026 Financial Results and Business Update
May 12, 2026
Closed $11.39 (-1.3%) on May 12, 2026
Immatics N.V. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 80 in all · newest Nov 10, 2026 · oldest 2020
- Decks
- 54 decks · latest Oct 26, 2026
Where Immatics N.V. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IMTX · Home listing | NASDAQ | United States | USD |
| Tradegate:4A3 | Tradegate | Germany | EUR |
| Frankfurt:4A3 | Frankfurt | Germany | EUR |
| gettex:4A3 | gettex | Germany | EUR |
| LS Exchange:A2P72S · This page | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2P72S | Lang & Schwarz | Germany | EUR |
| Stuttgart:4A3 | Stuttgart | Germany | EUR |
| BOATS:IMTX | BOATS | United States | USD |
| Dusseldorf:4A3 | Dusseldorf | Germany | EUR |
| Hamburg:4A3 | Hamburg | Germany | EUR |
| Munich:4A3 | Munich | Germany | EUR |
| Xetra:4A3 | Xetra | Germany | EUR |
| Hanover:4A3 | Hanover | Germany | EUR |
Valuation
EV/sales 7.9× against a median of 26.1×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $375.4M USD
- P/E
- Loss
- EV/sales
- 7.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.8×
- Gross margin
- 100.0%
- Operating margin
- −577.1%
- Net margin
- −534.1%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.40
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Immatics N.V. · NASDAQ:IMTX | US$878.3M | US$375.4M | n/a | 7.9× | n/a | 1.8× | −534.1% | 0.0× | 1.40 |
| MoonLake Immunotherapeutics · NASDAQ:MLTX | US$942.1M | US$543.7M | n/a | n/a | n/a | 2.5× | n/a | 0.3× | 1.32 |
| Savara, Inc. · NASDAQ:SVRA | US$939.9M | US$840.4M | n/a | n/a | n/a | 8.7× | n/a | 0.3× | 1.42 |
| Metis TechBio Co., Ltd. Class H · HKEX:7666 | US$918.1M | US$487.6M | n/a | 223× | n/a | 2.0× | −373.2% | 0.0× | n/a |
| InventisBio, Co., Ltd. Class A · SSE:688382 | US$897.5M | US$712.7M | n/a | 67.0× | n/a | 4.6× | −533.7% | 0.0× | n/a |
| InnoCare Pharma Ltd. Class A · SSE:688428 | US$894.7M | −US$209.0M | 9.3× | −0.6× | −2.3× | 0.8× | 27.1% | 0.1× | n/a |
| Bio-Thera Solutions, Ltd. Class A · SSE:688177 | US$878.1M | US$924.2M | n/a | 5.9× | n/a | 137× | −42.0% | 14.3× | n/a |
| Suzhou Ribo Life Science Co. Ltd. Class H · HKEX:6938 | US$875.5M | US$580.6M | n/a | 26.1× | n/a | 3.4× | −187.2% | 0.2× | n/a |
| Aktis Oncology, Inc. · NASDAQ:AKTS | US$868.0M | US$385.9M | n/a | 31.2× | n/a | 1.9× | −706.8% | 0.0× | 1.21 |
| Latigo Biotherapeutics, Inc. · NASDAQ:LTGO | US$861.9M | US$460.7M | n/a | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Pharming Group NV · EURONEXT:PHARM | US$840.1M | US$766.3M | 34.4× | 2.0× | 19.8× | 2.9× | 6.3% | 0.4× | n/a |
| Median of the others | US$886.4M | US$562.1M | 21.9× | 26.1× | 8.7× | 2.7× | −187.2% | 0.2× | 1.32 |
Forecasts
9 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 16.40 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.11 · 3 analysts
- Revenue, year to Dec 2026
- 35.85M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Harpreet Singh | Co-Founder, Chief Executive Officer |
| Venkat Ramanan | Chief Financial Officer |
| Jim Pepin | General Counsel, Corporate Secretary |
| Jürgen Richert | Vice President of Information Technology |
| Kerry Sieger | Vice President Global Quality Operations |
| Ali Mohamed | Head of Process Development |
| Amie Krause | Chief People Officer |
| Andrea Mayer-Mokler | Head of Clinical Development, Europe |
| Carsten Reinhardt | Chief Development Officer |
| Cedrik Britten | Chief Medical Officer |
| Chris Seal | Head of National Accounts and Sales |
| Michael Mølhøj | Head of CMC Biologics |
| Miriam Meyer | Senior Director and Head of Regulatory Affairs |
| Norbert Hilf | Head of Translational Development |
| Rainer Kramer | Chief Business Officer |
| Steffen Walter | Chief Operations Officer |
| Toni Weinschenk | Chief Innovation Officer |
Board
| Director | Role |
|---|---|
| Peter Chambré | Chair of the Board of Immatics N.V. |
| Adam Stone | Non-Executive Director |
| Alise Reicin | Board Member |
| Eliot Forster | Non-Executive Director |
| Harpreet Singh | Co-Founder, Chief Executive Officer |
| Heather L. Mason | Non-Executive Director |
| Mathias Hothum | Board Member |
| Michael G. Atieh | Non-Executive Director |
| Paul Carter | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −0.2% |
| Q2 2026 | Aug 18, 2026 · Before open | −1.7% |
| Q1 2026 | May 12, 2026 · Before open | −1.3% |
| Q4 2025 | Mar 25, 2026 | +6.2% |
| Q3 2025 | Nov 17, 2025 · Before open | −7.2% |
| Q2 2025 | Aug 13, 2025 · Before open | −5.0% |
| Q1 2025 | May 13, 2025 · Before open | −4.8% |
| Q4 2024 | Mar 19, 2025 · Before open | +5.1% |
| Q3 2024 | Nov 18, 2024 · Before open | −4.3% |
| Q2 2024 | Aug 13, 2024 · Before open | +1.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | +5.5% |
| Q4 2023 | Mar 21, 2024 · Before open | −5.9% |
| Q3 2023 | Nov 14, 2023 · Before open | +1.5% |
| Q2 2023 | Aug 17, 2023 · Before open | +1.9% |
| Q1 2023 | May 16, 2023 · Before open | −2.0% |
| Q4 2022 | Mar 21, 2023 · Before open | −0.8% |
| Q3 2022 | Nov 17, 2022 · Before open | −0.5% |
| Q2 2022 | Aug 9, 2022 · Before open | −3.6% |
| Q1 2022 | Jun 2, 2022 · Before open | +3.2% |
| Q4 2021 | Mar 23, 2022 · Before open | +1.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 63 slides | Oct 26, 2026 |
| Technical Presentation (October 2026) | Technical | 29 slides | Oct 26, 2026 |
| Technical Presentation (October 2026) | Technical | 23 slides | Oct 23, 2026 |
| Investor Presentation (August 2026) | Investor deck | 59 slides | Aug 18, 2026 |
| Conference Presentation (June 2026) | Conference | 25 slides | Jun 1, 2026 |
| Investor Presentation (March 2026) | Investor deck | 54 slides | Mar 5, 2026 |
| Investor Presentation (January 2026) | Investor deck | 54 slides | Jan 12, 2026 |
| Investor Presentation (December 2025) | Investor deck | 54 slides | Dec 11, 2025 |
| Technical Presentation (December 2025) | Technical | 18 slides | Dec 11, 2025 |
| 2025 ESMO Immuno-Oncology Congress | Conference | 16 slides | Dec 11, 2025 |
Show 50 decks
This page holds 50 of 54 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Public offering of ordinary shares and pre-funded warrants Announced: US$150M · US$8.69 a share · Jefferies +2 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Cantor (co-lead) | Aug 25, 2026 |
| Public offering of ordinary shares Announced: US$125M · US$10 a share · Jefferies +2 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Cantor (co-lead) | Dec 5, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 48.3M | 155.8M | 54.0M | 172.8M | 34.8M | 31.3M | 18.4M | 3.77M |
| Cost of revenue | 148.1M | 118.7M | 106.8M | 87.6M | 67.1M | 40.1M | 34.0M | |
| Gross profit | 48.3M | 155.8M | 54.0M | 172.8M | 34.8M | -35.8M | -21.6M | -30.2M |
| Research and development | 183.8M | 148.1M | 118.7M | 106.8M | 87.6M | 67.1M | 40.1M | 34.0M |
| Selling, general and administrative | 51.2M | 46.4M | 38.2M | 36.1M | 33.8M | 34.1M | 11.8M | 7.67M |
| Operating income | -182.0M | -38.6M | -101.7M | 30.0M | -86.3M | -69.7M | -33.0M | -34.4M |
| Depreciation and amortization | 12.4M | 12.2M | 7.23M | 6.97M | 5.26M | 4.42M | 3.86M | 2.18M |
| EBITDA | -169.6M | -26.4M | -94.5M | 36.9M | -81.0M | -65.3M | -29.2M | -32.2M |
| Interest expense | 946.0K | 886.0K | 831.0K | 1.04M | 566.0K | 289.0K | 264.0K | 161.0K |
| Income before tax | -198.4M | 21.3M | -97.0M | 42.0M | -93.3M | -211.8M | -32.5M | -32.4M |
| Income tax | -1.99M | 6.13M | -2.35M | 14.3M | 0 | 0 | 0 | 0 |
| Net income | -196.4M | 15.2M | -94.6M | 27.7M | -93.3M | -211.3M | -31.6M | -31.4M |
| Earnings per share, basic | -1.61 | 0.14 | -1.18 | 0.41 | -1.48 | -4.40 | -0.50 | -0.50 |
| Earnings per share, diluted | -1.61 | 0.14 | -1.18 | 0.40 | -1.48 | -4.40 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 345.9M | 236.7M | 218.5M | 148.5M | 133.0M | 207.5M | 103.4M | 39.4M |
| Short-term investments | 123.4M | 367.7M | 207.4M | 213.7M | 12.1M | 24.4M | 16.0M | 13.1M |
| Receivables | 6.10M | 5.86M | 4.09M | 1.11M | 682.0K | 1.25M | 957.0K | 1.82M |
| Inventory | 1 | 1 | 1 | 3.30M | 1.24M | 1 | ||
| Current assets | 504.0M | 629.6M | 449.4M | 377.2M | 152.2M | 239.0M | 124.0M | 55.3M |
| Property, plant and equipment | 42.1M | 50.4M | 43.7M | 13.5M | 10.5M | 7.87M | 4.72M | 4.01M |
| Total assets | 562.3M | 696.1M | 510.0M | 407.8M | 174.6M | 254.6M | 134.3M | 61.3M |
| Accounts payable | 18.8M | 20.7M | 25.2M | 13.1M | 11.6M | 10.1M | 7.08M | 4.80M |
| Current liabilities | 43.0M | 68.0M | 156.6M | 106.5M | 95.1M | 77.5M | 69.3M | 26.8M |
| Total debt | 15.6M | 16.2M | 15.4M | 14.6M | 9.85M | 6.19M | 3.23M | |
| Total liabilities | 78.2M | 121.3M | 292.3M | 204.5M | 150.6M | 167.3M | 175.1M | 70.5M |
| Shareholders' equity | 484.1M | 574.8M | 217.6M | 203.4M | 24.1M | 87.4M | -41.9M | -9.17M |
| Shares outstanding | 122.3M | 106.8M | 80.5M | 68.2M | 62.9M | 62.9M | 62.9M | 62.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -176.6M | -158.0M | 18.2M | 100.1M | -84.7M | -80.7M | 71.0M | 20.7M |
| Capital spending | -6.56M | -16.3M | -30.8M | -5.74M | -5.11M | -7.42M | -2.14M | -429.0K |
| Free cash flow | -183.2M | -174.3M | -12.6M | 94.4M | -89.9M | -88.1M | 68.8M | 20.3M |
| Cash from investing | 204.8M | -152.4M | -31.4M | -209.8M | 7.49M | -15.9M | -5.06M | -13.5M |
| Cash from financing | 97.4M | 319.7M | 84.5M | 123.7M | -2.61M | 207.9M | -1.86M | 23.6M |
| Share buybacks | 149.7M | |||||||
| Change in cash | 125.5M | 9.27M | 71.4M | 14.1M | -79.9M | 111.2M | 64.0M | 30.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 10, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 26, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 23, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
Show 200 filings
This page holds 200 of 250 filings. Open Filings
Cap table
Built by 6ix from Immatics N.V.’s releases · as of Aug 25, 2026
- Common shares
- 152,225,077
- Fully diluted
- 152,225,077
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 152,225,077 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 152,225,077 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Adam Stone Other companies: Solid Biosciences Inc. (Director · Since at least Jan 25, 2018); Freenome, Inc. (Chief Executive Officer, Director · Jun 11, 2024 – Jun 13, 2024 · Past); ARYA Sciences Acquisition Corp V (Chief Executive Officer, Director · Jul 12, 2021 – Jul 15, 2021 · Past); ARYA Sciences Acquisition IV Corp (Chief Executive Officer, Director · Feb 25, 2021 – Jul 31, 2024 · Past); Nautilus Biotechnology, Inc. (Chief Executive Officer, Director · Aug 6, 2020 – Aug 11, 2020 · Past); Cerevel Therapeutics Holdings Inc (Chief Executive Officer, Director · Jun 4, 2020 – Jun 9, 2020 · Past); ARYA Sciences Acquisition Corp (Chief Executive Officer, Director · Oct 5, 2018 – Oct 5, 2018 · Past) | Non-Executive Director · Since at least Mar 18, 2026 |
| Michael G. Atieh Other companies: Chubb Limited (Director · Since at least May 19, 2010); Oyster Point Pharma Inc (Director · Oct 8, 2020 – Jan 3, 2023 · Past); electroCore, Inc. (Director · Jun 21, 2018 – Jun 11, 2021 · Past); IVERIC bio Inc (EVP, CFO, & CBO, Treasurer · Sep 30, 2014 – Jan 2, 2016 · Past); Theravance Biopharma, Inc. (Director · Jun 3, 2014 – Jun 3, 2014 · Past) | Non-Executive Director · Since at least Mar 18, 2026 |
| Alise Reicin Other companies: Tectonic Therapeutic, Inc. (President and CEO, Director · Since at least Jun 20, 2024); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Q32 Bio Inc. (Director · Jul 11, 2019 – Jun 14, 2023 · Past); Celgene Corporation (PRES., GLOBAL CLINICAL DEV. · Nov 1, 2018 – Nov 20, 2019 · Past) | Director · Since at least Mar 18, 2026 |
| Paul Carter Other companies: Mallinckrodt Inc (Director · May 16, 2018 – Jun 16, 2022 · Past); Alder BioPharmaceuticals Inc (Director · Sep 28, 2015 – Oct 22, 2019 · Past); Gilead Sciences, Inc. (EVP Commercial Ops · Jul 1, 2015 – Aug 1, 2016 · Past) | Non-Executive Director · Since at least Mar 18, 2026 |
| Eliot Forster Other companies: Protalix BioTherapeutics, Inc. (de) (Chairman · Since at least Sep 14, 2023) | Non-Executive Director · Since at least Mar 18, 2026 |
| Joseph Edelman Other companies: Kardigan, Inc. (Director · Since at least Jun 17, 2026) | Director · Since at least Aug 26, 2026 |
| Venkat Ramanan Other companies: Turnstone Biologics Corp. (Chief Financial Officer · Jul 20, 2023 – Oct 16, 2023 · Past) | Chief Financial Officer · Since at least Mar 5, 2026 |
| Ali Mohamed | Head of Process Development · Since at least Nov 4, 2026 |
| Amie Krause | Chief People Officer · Since at least Mar 5, 2026 |
| Andrea Mayer-Mokler | Head of Clinical Development, Europe · Since at least Nov 4, 2026 |
All 30 people
| Person | Seat |
|---|---|
| Carsten Reinhardt | Chief Development Officer · Since at least Mar 18, 2026 |
| Cedrik Britten | Chief Medical Officer · Since at least Mar 18, 2026 |
| Chris Seal | Head of National Accounts and Sales · Since at least Nov 4, 2026 |
| Edward A Sturchio Jr | General Counsel · Since at least Mar 18, 2026 |
| Harpreet Singh | Co-Founder, Chief Executive Officer · Since at least Aug 18, 2026 |
| Heather L. Mason | Non-Executive Director · Since at least Nov 5, 2026 |
| James Nelson Pepin | Gen Counsel and Corp Secretary · Since at least Jul 20, 2026 |
| Jasuja Harpreet Singh | Chief Executive Officer, Director · Since at least Mar 18, 2026 |
| Jim Pepin | General Counsel, Corporate Secretary · Since at least Aug 18, 2026 |
| Jordan Zeik Silverstein | Head of Strategy · Since at least Mar 18, 2026 |
| Jürgen Richert | Vice President of Information Technology · Since at least Nov 5, 2026 |
| Kerry Sieger | Vice President Global Quality Operations · Since at least Nov 5, 2026 |
| Mathias Hothum | Board Member · Since at least Mar 17, 2026 |
| Michael Mølhøj | Head of CMC Biologics · Since at least Nov 5, 2026 |
| Miriam Meyer | Senior Director and Head of Regulatory Affairs · Since at least Nov 5, 2026 |
| Norbert Hilf | Head of Translational Development · Since at least Nov 4, 2026 |
| Peter Chambré | Chair of the Board of Immatics N.V. · Since at least Mar 18, 2026 |
| Rainer Kramer | Chief Business Officer · Since at least Mar 18, 2026 |
| Steffen Walter | Chief Operations Officer · Since at least Nov 5, 2026 |
| Toni Weinschenk | Chief Innovation Officer · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about Immatics N.V.